Vanita R. Aroda, MD - Leveraging Early GLP-1 RA Initiation to Reduce Risks and Improve Long-Term Outcomes in Patients With T2DM - a podcast by PVI, PeerView Institute for Medical Education

Go online to PeerView.com/WEU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. People with type 2 diabetes mellitus (T2DM) deserve care that is timely and of the appropriate intensity to reduce risks and improve long-term outcomes. To that end, GLP-1 receptor agonists (RAs) must be considered in a new light. Their role has escalated in recent years, including their positioning in treatment, due to their multifaceted mechanisms of action and the collective body of evidence validating their glycemic and extra-glycemic effects. In fact, these agents have consistently demonstrated high glycemic efficacy while reducing cardiovascular and renal risks with a favorable impact on weight and a low risk of hypoglycemia in patients with T2DM. Watch this expert-led activity to learn about GLP-1 RA options and get practical advice for integrating them into personalized care. Upon completion of this activity, participants should be better able to: Differentiate GLP-1 RAs and other glucose-lowering agents with regard to their current placement in treatment guidelines, glycemic and extra-glycemic effects, safety, ease of administration, and dosing frequency; Identify people with T2DM who would benefit from the glycemic and extra-glycemic effects of GLP-1 RAs to reduce cardiometabolic and renal risks, improve long-term health outcomes, and increase treatment adherence; and Incorporate GLP-1 RAs into personalized treatment regimens early to reduce cardiometabolic and renal risks in people with T2DM

Further episodes of PeerView Endocrinology

Further podcasts by PVI, PeerView Institute for Medical Education

Website of PVI, PeerView Institute for Medical Education